Nothing Special   »   [go: up one dir, main page]

NO20063155L - Anti-IGF-I receptor antibody - Google Patents

Anti-IGF-I receptor antibody

Info

Publication number
NO20063155L
NO20063155L NO20063155A NO20063155A NO20063155L NO 20063155 L NO20063155 L NO 20063155L NO 20063155 A NO20063155 A NO 20063155A NO 20063155 A NO20063155 A NO 20063155A NO 20063155 L NO20063155 L NO 20063155L
Authority
NO
Norway
Prior art keywords
igf
antibodies
receptor
cancer
elevated level
Prior art date
Application number
NO20063155A
Other languages
Norwegian (no)
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of NO20063155L publication Critical patent/NO20063155L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Antistoffer, humaniserte antistoffer, overflatemodifiserte antistoffer,antistoffragmenter, derivatiserte antistoffer og konjugater av disse med cytotoksiske midler, som spesifikt bindes til og inhiberer insulinlignende vekstfaktor-1-reseptor, antagoniserer virkningene av IGF-I, IGF-II og serum på vekst og overlevelse av tumorceller og som i det vesentlige er frie for agonistaktivitet. Antistoffene og fragmentene av disse kan, om ønskelig sammen med andre terapeutiske midler, anvendes ved behandling av tumorer som uttrykker forhøyet nivå av IGF-I-reseptor, feks. brystkreft, kolonkreft, lungekreft, ovariekarsinom, synovialkarsinom, prostatakreft og bukspyttkjertelkreft, og de derivatiserte antistoffene kan anvendes ved diagnose og synliggjøring av tumorer som uttrykker forhøyet nivå av IGF-I-reseptor.Antibodies, humanized antibodies, surface-modified antibodies, antibody fragments, derivatized antibodies and their conjugates with cytotoxic agents that specifically bind to and inhibit insulin-like growth factor-1 receptor antagonize the effects of IGF-I, IGF-II, and serum on growth. tumor cells and which are essentially free of agonist activity. The antibodies and fragments thereof, if desired together with other therapeutic agents, may be used in the treatment of tumors expressing elevated level of IGF-I receptor, e.g. breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial carcinoma, prostate cancer and pancreatic cancer, and the derivatized antibodies can be used in the diagnosis and visualization of tumors expressing elevated level of IGF-I receptor.

NO20063155A 2003-12-08 2006-07-07 Anti-IGF-I receptor antibody NO20063155L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (1)

Publication Number Publication Date
NO20063155L true NO20063155L (en) 2006-08-11

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063155A NO20063155L (en) 2003-12-08 2006-07-07 Anti-IGF-I receptor antibody

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2515941T3 (en) 2009-12-21 2020-04-30 F. Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
MX2012013068A (en) * 2010-05-11 2013-03-05 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies.
WO2013055699A1 (en) * 2011-10-10 2013-04-18 Children's Hospital Los Angeles Novel asparaginase and methods for treating diseases associated with asparagine dependence
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
KR20190138672A (en) * 2017-05-30 2019-12-13 데이진 화-마 가부시키가이샤 Anti IGF-I Receptor Antibodies
CN118615438A (en) * 2023-03-07 2024-09-10 康方药业有限公司 Drug combination comprising anti-CTLA4-anti-PD-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (en) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. Uses of anti-insulin-like growth factor ⅰ receptor antibodies

Also Published As

Publication number Publication date
CA2548065A1 (en) 2005-07-07
EA200600931A1 (en) 2006-10-27
CR8426A (en) 2007-12-04
EP1692176A4 (en) 2008-11-12
IL174770A0 (en) 2006-08-20
AU2004303792A1 (en) 2005-07-07
KR20070001883A (en) 2007-01-04
BRPI0417406A (en) 2007-04-03
EA009807B1 (en) 2008-04-28
CN1886424A (en) 2006-12-27
MXPA06005540A (en) 2006-08-17
ECSP066595A (en) 2006-10-17
JP2008502589A (en) 2008-01-31
EP1692176A1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
SG141243A1 (en) Anti-igf-i receptor antibody
Ristau et al. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research
Fong et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer
Lo et al. Anaplastic carcinoma of the thyroid
EA200970130A1 (en) ANTAGONISTIC ANTIBODE FOR CANCER TREATMENT
Errarte et al. The expression of fibroblast activation protein in clear cell renal cell carcinomas is associated with synchronous lymph node metastases
ATE509033T1 (en) ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING
MX2021015888A (en) Fusion of an antibody binding cea and 4-1bbl.
WO2006099141A3 (en) Anti-mesothelin antibodies
NO20063155L (en) Anti-IGF-I receptor antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
Bai et al. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related
MX2009012838A (en) Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label.
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2007149948A3 (en) Compositions and methods for diagnosis and treatment of tumors
Fenton et al. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
EA200601405A1 (en) HUMANIZED ANTIBODY
EP1539818A4 (en) Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
Zhu et al. Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis
WO2008131575A3 (en) Anti-alk antibodies suitable for treating metastatic cancers or tumors
DE69829001D1 (en) HUMANIZED MONOCLONAL ANTIBODIES WITH HIGH AFFINITY AGAINST DAY-72
NO20004251L (en) Humanized anti-CEA high affinity monoclonal antibodies
Pawlikowski et al. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation
Yildirim et al. Concurrent epithelioid malignant peripheral nerve sheath tumor and papillary thyroid carcinoma in the treated field of Hodgkin's disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application